Cholesterol-lowing therapies using statins or proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors have been confirmed to mitigate stroke risk proportionally with the degree of reduction in cholesterol levels [8, 66, 67]. Here, PCSK9 is linked to stroke disorder.